Literature DB >> 22866132

Clinical features of malignant melanoma of the finger and therapeutic efficacies of different treatments.

Zuozhang Yang1, Lin Xie, Yunchao Huang, Hongpu Sun, Tao Yuan, Xiang Ma, Congguo Jing, Pengjie Liu.   

Abstract

The purpose of this study was to explore the clinical features of malignant melanoma of the finger and therapeutic efficacies of different treatments. The clinical data of 22 patients with malignant melanoma of the finger (confirmed by pathological examination), admitted and treated in our hospital between February 1995 and October 2007, were analyzed retrospectively. The primary site of the tumor was the thumb in 12 cases, index finger in 3 cases, middle finger in 3 cases, ring finger in 2 cases and little finger in 2 cases. The most common presenting symptoms were pain and black patches on the fingers. A total of 15 of the 22 patients had subungual disease, 12 had a history of trauma and 2 had osteolytic bone lesions of the phalanx. The main treatments employed were surgery, chemotherapy and immunotherapy. Finger amputation was performed for all 22 patients and axillary lymph node dissection in the same side was performed for 13 patients. Nineteen cases were followed up for 1-10 years with an average of 5.5 years. Three patients were lost to follow-up 2 years after treatment. The 1-, 3- and 5-year survival rates were 86.4% (19/22), 42.1% (12/19) and 31.2% (6/19), respectively. In conclusion, malignant melanoma of the finger is a rarely occurring tumor. Comprehensive treatment, including surgery, chemotherapy and immunotherapy, is the key approach for malignant melanoma of the finger. Prognosis of the disease is associated with the size of the tumor, depth of infiltration and clinical stages.

Entities:  

Year:  2011        PMID: 22866132      PMCID: PMC3408097          DOI: 10.3892/ol.2011.324

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  9 in total

1.  Biochemotherapy for advanced melanoma: maybe it is real.

Authors:  David Khayat; Chantal Bernard-Marty; Jean-Baptiste Meric; Olivier Rixe
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 2.  Chemotherapy for metastatic melanoma: time for a change?

Authors:  Helen J Gogas; John M Kirkwood; Vernon K Sondak
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

3.  Surgical management of primary cutaneous melanomas of the hands and feet.

Authors:  J F Tseng; K K Tanabe; M A Gadd; A B Cosimi; R A Malt; F G Haluska; M C Mihm; A J Sober; W W Souba
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma.

Authors:  P Hersey
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 5.  Cytokine-based therapy and biochemotherapy for advanced melanoma.

Authors:  Michael B Atkins
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.

Authors:  D L Morton
Journal:  Dev Biol (Basel)       Date:  2004

7.  [Therapeutic result of operation combined with large-dose of roferon-A for cutaneous malignant melanoma].

Authors:  Yaojun Wang; Ying Cen; Zhengyong Li
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2007-01

Review 8.  Treatment of malignant melanoma.

Authors:  E Durán García; R Santolaya; T Requena
Journal:  Ann Pharmacother       Date:  1999-06       Impact factor: 3.154

Review 9.  Adoptive cellular therapy.

Authors:  D M Hoffman; B J Gitlitz; A Belldegrun; R A Figlin
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

  9 in total
  1 in total

1.  Effects of heavy ions (12C6+) on malignant melanoma B16F10 cells.

Authors:  Li-Ping Zhang; Sha Li; Hong Zhang; Qiang Li; Yang Liu; Fei-Fei Li; Da-Jie Gong
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.